Skip the wait and schedule your appointments online or through MyChart.

COVID Vaccine Now Available for Ages 6 months+ – Learn More

Research & Innovation

Pancreatic Clinical Trials

Clinical Trials

Angiodynamics 2019-ONC-02

Physician & Study Coordinator

Physician

Dr. Darius Desai

Study Coordinator

Janine Schippang
484-658-1790

JanineL.Schippang@sluhn.org

Close

Synopsis

Synopsis: Registry Trial To Evaluate Effectiveness And Safety Of The Nanoknife System For TheAblation Of Stage 3 Pancreatic Adenocarcinoma

Close

Eligibility Criteria
  • Patients with histologically or cytologically confirmed Stage 3 pancreas cancer who aretreated, in real-world treatment settings and as part of routine clinical practice, with theNanoKnife System for the ablation of their tumor in addition to SOC (IRE cohort), or withSOC only (SOC cohort)
  • Patients will be enrolled after completing the initial 3-month treatment per SOC
  • Maximum axial and anterior to posterior tumor dimension of ≤3.5cm after 3 monthsstandard of care chemotherapy

Close

Angiodynamics 28-001-ONC

Physician & Study Coordinator

Physician

Darius Desai MD

Study Coordinator

Janine Schippang
484-658-1790

JanineL.Schippang@sluhn.org

Close

Synopsis

Synopsis: A Randomized, Multicenter, Controlled, Unblinded Study to Assess the Safetyand Efficacy of the NanoKnife System for the Ablation of Unresectable Stage 3 PancreaticAdenocarcinoma

Close

Eligibility Criteria
  • Is ≥18 years of age, at the time of signing the informed consent
  • Unresectable stage III pancreatic adenocarcinoma cancer
  • Patient has received 3 months of modified FOLFIRINOX regimen
  • Maximum axial and anterior to posterior tumor dimension of ≤3.5cm after 3 months ofmodified FOLFIRINOX.

Close

ECOG-ACRIN 2185

Physician & Study Coordinator

Physician

Darius Desai MD

Study Coordinator

Vivian Colon
484-658-1793

vivian.colon@sluhn.org

Close

Synopsis

Synopsis: Comparing the Clinical Impact of Pancreatic Cyst Suveillance Programs

Close

Eligibility Criteria
  • Patients must have completed a CT, MRI or EUS within 6 months prior to randomization thatreveals one or more ≥ 1 cm pancreatic cyst(s)
  • No prior diagnosis of pancreatic malignancy of any type
  • No prior history pancreatic resection
  • Patients with pancreatic lesions without malignant risk (pseudo cyst or classic cystic lesions)are not eligible
  • No family pancreatic history of pancreatic adenocarcinoma in one or more first degreerelatives
  • Patients must have be ≥ 50 years and ≤ 75 years of age

Close